DK1383786T3 - Antiinflammatoriske 17-beta-carbothioatesterderivater af androstan med en cyklisk estergruppe i 17alfa-stilling - Google Patents
Antiinflammatoriske 17-beta-carbothioatesterderivater af androstan med en cyklisk estergruppe i 17alfa-stillingInfo
- Publication number
- DK1383786T3 DK1383786T3 DK02722463T DK02722463T DK1383786T3 DK 1383786 T3 DK1383786 T3 DK 1383786T3 DK 02722463 T DK02722463 T DK 02722463T DK 02722463 T DK02722463 T DK 02722463T DK 1383786 T3 DK1383786 T3 DK 1383786T3
- Authority
- DK
- Denmark
- Prior art keywords
- 17alpha
- androstan
- inflammatory
- beta
- carbothioate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0110578A GB0110578D0 (en) | 2001-04-30 | 2001-04-30 | Novel compounds |
GB0127988A GB0127988D0 (en) | 2001-11-22 | 2001-11-22 | Novel compounds |
GB0202442A GB0202442D0 (en) | 2002-02-02 | 2002-02-02 | Novel compounds |
GB0202637A GB0202637D0 (en) | 2002-02-05 | 2002-02-05 | Novel compounds |
PCT/GB2002/001971 WO2002088167A1 (en) | 2001-04-30 | 2002-04-30 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1383786T3 true DK1383786T3 (da) | 2009-01-12 |
Family
ID=27447944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02722463T DK1383786T3 (da) | 2001-04-30 | 2002-04-30 | Antiinflammatoriske 17-beta-carbothioatesterderivater af androstan med en cyklisk estergruppe i 17alfa-stilling |
Country Status (25)
Country | Link |
---|---|
US (2) | US7291608B2 (da) |
EP (2) | EP2039700A2 (da) |
JP (1) | JP4446661B2 (da) |
KR (1) | KR100831534B1 (da) |
CN (1) | CN1302007C (da) |
AR (1) | AR033290A1 (da) |
AT (1) | ATE411334T1 (da) |
AU (2) | AU2002253342B2 (da) |
BR (1) | BR0209271A (da) |
CA (1) | CA2445839A1 (da) |
CZ (1) | CZ20032958A3 (da) |
DE (1) | DE60229372D1 (da) |
DK (1) | DK1383786T3 (da) |
ES (1) | ES2314052T3 (da) |
HK (1) | HK1062020A1 (da) |
HU (1) | HUP0400070A2 (da) |
IL (1) | IL158222A0 (da) |
MX (1) | MXPA03009940A (da) |
MY (1) | MY137522A (da) |
NO (1) | NO326015B1 (da) |
NZ (1) | NZ528888A (da) |
PL (1) | PL366937A1 (da) |
PT (1) | PT1383786E (da) |
SI (1) | SI1383786T1 (da) |
WO (1) | WO2002088167A1 (da) |
Families Citing this family (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
BR0209271A (pt) * | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
AU2002356759A1 (en) * | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
AU2003202044A1 (en) * | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
CA2506956C (en) * | 2002-11-27 | 2012-10-02 | Altana Pharma Ag | Synergistic combination comprising roflumilast and (r,r)-formoterol |
WO2004047829A1 (en) * | 2002-11-27 | 2004-06-10 | Altana Pharma Ag | New synergistic combination comprising roflumilast and formoterol |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JP4778053B2 (ja) | 2005-07-14 | 2011-09-21 | リセラ,インコーポレイテッド | 局所的脂肪組織処置のための徐放性増強脂肪分解処方物 |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
NZ566068A (en) | 2005-08-08 | 2011-03-31 | Argenta Discovery Ltd | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
TW200744612A (en) * | 2005-08-26 | 2007-12-16 | Astrazeneca Ab | New combination |
EP2532678A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
EA200801997A1 (ru) | 2006-04-20 | 2009-04-28 | Глаксо Груп Лимитед | Новые соединения |
PT2013211E (pt) | 2006-04-21 | 2012-06-21 | Novartis Ag | Derivados de purina para utilização como agonistas de receptores a2a de adenosina |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
TW200821316A (en) | 2006-07-19 | 2008-05-16 | Astrazeneca Ab | Novel compounds 243 |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
ATE555111T1 (de) | 2006-12-19 | 2012-05-15 | Astrazeneca Ab | Chinuclidinol-derivate als muscarinrezeptor- antagonisten |
WO2008085608A1 (en) | 2007-01-10 | 2008-07-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
MX2009008493A (es) | 2007-02-09 | 2009-08-20 | Irm Llc | Compuestos y composiciones como inhibidores de la proteasa activadora de canal. |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
PL2155721T3 (pl) | 2007-05-07 | 2011-07-29 | Novartis Ag | Związki organiczne |
US8048980B2 (en) * | 2007-09-17 | 2011-11-01 | Bezwada Biomedical, Llc | Hydrolysable linkers and cross-linkers for absorbable polymers |
WO2009044200A1 (en) * | 2007-10-04 | 2009-04-09 | Astrazeneca Ab | Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity |
CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
PL2231642T3 (pl) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pirymidyny jako inhibitory kinazy |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
EP2300464A1 (en) | 2008-05-13 | 2011-03-30 | AstraZeneca AB | Quinuclidine derivatives as muscarinic m3 receptor antagonists |
JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ,エルエルシー. | 5−リポキシゲナーゼ活性化タンパク質阻害剤 |
US8273774B2 (en) | 2008-05-27 | 2012-09-25 | Astrazeneca Ab | Phenoxypyridinylamide compounds |
ES2566339T3 (es) | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
BRPI0915018A2 (pt) | 2008-06-10 | 2015-10-27 | Novartis Ag | compostos orgânicos |
WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
US8362064B2 (en) | 2008-12-30 | 2013-01-29 | Pulmagen Theraputics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドGlaxo Group Limited | Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
CN102439151A (zh) | 2009-03-19 | 2012-05-02 | 默沙东公司 | 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制 |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411019A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
SG174581A1 (en) | 2009-03-27 | 2011-10-28 | Merck Sharp & Dohme | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
UY32520A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides |
UY32525A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
UY32523A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
UY32521A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Combinación para emplear en el tratamiento de enfermedades respiratorias |
WO2010122089A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
DK2899191T3 (da) | 2009-04-30 | 2017-11-13 | Glaxo Group Ltd | Oxazol-substituerede indazoler som pi3-kinaseinhibitorer |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
EA201200318A1 (ru) | 2009-08-20 | 2012-09-28 | Новартис Аг | Гетероциклические оксимы |
AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3−キナーゼ阻害剤としてのインダゾール誘導体 |
JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
GB2487868B (en) * | 2010-01-15 | 2014-12-10 | Neothetics Inc | Lyophilized cake formulations |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
CN102250185B (zh) * | 2010-05-19 | 2015-06-10 | 天津金耀集团有限公司 | 一种21位为nmda酯的糖皮质激素 |
RS54286B1 (en) | 2010-09-08 | 2016-02-29 | Glaxosmithkline Intellectual Property Development Limited | POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide |
JP5876051B2 (ja) | 2010-09-08 | 2016-03-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体 |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドGlaxo Group Limited | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
GB2485885B (en) | 2010-11-24 | 2015-06-17 | Neothetics Inc | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
CA2828219A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
EP2683716A1 (en) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
CN102850426B (zh) * | 2011-07-01 | 2015-12-02 | 天津金耀集团有限公司 | 一种21位为n-乙酰半胱氨酸酯的糖皮质激素 |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
MX339302B (es) | 2011-09-15 | 2016-05-19 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013078440A2 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
EP3007697B1 (en) | 2013-06-14 | 2020-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1 inhibitors for inducing bronchodilation |
JP6475707B2 (ja) | 2013-10-17 | 2019-02-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
EA032075B1 (ru) | 2014-04-24 | 2019-04-30 | Новартис Аг | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы |
CA2945257A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
RU2695230C2 (ru) | 2014-07-31 | 2019-07-22 | Новартис Аг | Сочетанная терапия |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CN113891744A (zh) | 2019-06-10 | 2022-01-04 | 诺华股份有限公司 | 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物 |
EP4021572A1 (en) | 2019-08-28 | 2022-07-06 | Novartis AG | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
EP4125919A1 (en) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR580494A (fr) | 1923-07-10 | 1924-11-07 | Const Metalliques Schiltigheim | Procédé d'établissement des buses d'aération ou autres tuyaux |
US2837464A (en) * | 1955-01-11 | 1958-06-03 | Schering Corp | Process for production of dienes by corynebacteria |
DE1059906B (de) | 1954-10-05 | 1959-06-25 | Scherico Ltd | Verfahren zur Herstellung von 1, 4-Pregnadienen |
US3067197A (en) | 1961-04-26 | 1962-12-04 | Pfizer & Co C | 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives |
GB1047518A (en) * | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
GB1159490A (en) | 1966-02-09 | 1969-07-23 | Boots Pure Drug Co Ltd | Improvements in Acylated Steroids |
US3639434A (en) * | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
GB1227992A (da) * | 1968-01-23 | 1971-04-15 | Koninklijke Gist Spiritus | |
IT1034011B (it) | 1969-06-26 | 1979-09-10 | Vister Vismara Terapeutici S P | Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato |
GB1384372A (en) | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
US3828080A (en) | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
US3989686A (en) | 1972-06-15 | 1976-11-02 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstane series and process for preparing same |
GB1438940A (en) | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
GB1440063A (en) * | 1972-08-11 | 1976-06-23 | Glaxo Lab Ltd | 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids |
DE2336693A1 (de) | 1973-07-19 | 1975-02-06 | Nassheuer Ind Ofenbau Jean | Strahlheizrohr |
GB1517278A (en) | 1974-08-30 | 1978-07-12 | Glaxo Lab Ltd | Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates |
US4093721A (en) | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
YU54476A (en) * | 1975-03-31 | 1982-05-31 | Taisho Pharmaceutical Co Ltd | Process for obtaining 17-ester 21-halo-pregnane |
DE2538569A1 (de) | 1975-08-29 | 1977-03-03 | Siemens Ag | Verfahren zur metallisierung von duroplasten |
CH628355A5 (de) | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
US4221787A (en) | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
US4198403A (en) | 1978-04-05 | 1980-04-15 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes |
US4188385A (en) | 1978-04-05 | 1980-02-12 | Syntex (U.S.A.) Inc. | Thioetianic acid derivatives |
US4187301A (en) | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
US4263289A (en) | 1978-04-05 | 1981-04-21 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
US4261984A (en) | 1978-04-05 | 1981-04-14 | Syntex (U.S.A.) Inc. | 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes |
DE2817988A1 (de) | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
US4310466A (en) | 1979-08-31 | 1982-01-12 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
US4267173A (en) | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
CY1291A (en) | 1980-02-15 | 1985-10-18 | Glaxo Group Ltd | Androstane 17 beta carbothioates |
PH24267A (en) | 1980-02-15 | 1990-05-29 | Glaxo Group Ltd | Androstane carbothioates and pharmaceutical compositions containing the same |
ZA814440B (en) | 1980-07-10 | 1982-10-27 | Otsuka Pharma Co Ltd | Soft steroids having anti-inflammatory activity |
US4710495A (en) | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
DE3260474D1 (en) | 1981-02-02 | 1984-09-06 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
CA1224992A (en) | 1982-10-08 | 1987-08-04 | Robert E. Newell | Device for administering medicament to patients |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4607028A (en) | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
LU85856A1 (fr) | 1984-04-17 | 1986-06-11 | Glaxo Group Ltd | Composes de phenethanolamine |
EP0179583A1 (en) | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
US4861765A (en) | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
FI88112C (fi) | 1985-07-30 | 1993-04-13 | Glaxo Group Ltd | Anordning foer administrering av laekemedel till patienter |
US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
FR2644787B1 (fr) | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 21 aminosubstitues, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
US5202316A (en) | 1989-03-22 | 1993-04-13 | Roussel Uclaf | N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines |
FR2644788B1 (fr) | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
JPH07116215B2 (ja) | 1989-04-19 | 1995-12-13 | エスエス製薬株式会社 | 新規なステロイド化合物 |
IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
DE4025342A1 (de) | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
US5250293A (en) | 1991-04-22 | 1993-10-05 | Gleich Gerald J | Method for the treatment of hypersensitivity diseases by administration of anionic polymers |
TW247878B (da) | 1991-07-02 | 1995-05-21 | Takeda Pharm Industry Co Ltd | |
US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
DE69413955T2 (de) | 1993-03-17 | 1999-04-01 | Minnesota Mining & Mfg | Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel |
DE4328819A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DE4333920A1 (de) | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
GB9419536D0 (en) | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
US5707984A (en) | 1995-12-08 | 1998-01-13 | G. D. Searle & Co. | Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs |
SK89198A3 (en) | 1995-12-29 | 1999-03-12 | Glaxo Group Ltd | Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives |
US5981517A (en) | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
US5919776A (en) | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US5972920A (en) | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
US6255303B1 (en) | 1998-03-14 | 2001-07-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone PDE III/IV inhibitors |
US6136294C1 (en) | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
US6261539B1 (en) | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
GB9828721D0 (en) | 1998-12-24 | 1999-02-17 | Glaxo Group Ltd | Novel apparatus and process |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20020081266A1 (en) | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
EP1305329B2 (en) | 2000-08-05 | 2015-03-18 | Glaxo Group Limited | 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyl)oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
CN1481246A (zh) | 2000-12-22 | 2004-03-10 | SS��ҩ��ʽ���� | 炎症性呼吸道疾病的预防/治疗剂 |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
BR0209271A (pt) * | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
US6787593B2 (en) * | 2002-03-27 | 2004-09-07 | Lear Corporation | Sound-deadening composites of metallocene copolymers for use in vehicle applications |
JP3691459B2 (ja) | 2002-06-14 | 2005-09-07 | 久光メディカル株式会社 | 粉末状吸入剤組成物 |
DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
BR0316108A (pt) * | 2002-11-08 | 2005-09-27 | Warner Lambert Co | Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos |
GB0526419D0 (en) | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
-
2002
- 2002-04-30 BR BR0209271-9A patent/BR0209271A/pt not_active IP Right Cessation
- 2002-04-30 EP EP08157256A patent/EP2039700A2/en not_active Withdrawn
- 2002-04-30 AU AU2002253342A patent/AU2002253342B2/en not_active Ceased
- 2002-04-30 PT PT02722463T patent/PT1383786E/pt unknown
- 2002-04-30 AR ARP020101587A patent/AR033290A1/es unknown
- 2002-04-30 AT AT02722463T patent/ATE411334T1/de not_active IP Right Cessation
- 2002-04-30 ES ES02722463T patent/ES2314052T3/es not_active Expired - Lifetime
- 2002-04-30 US US10/478,893 patent/US7291608B2/en not_active Expired - Fee Related
- 2002-04-30 EP EP02722463A patent/EP1383786B1/en not_active Expired - Lifetime
- 2002-04-30 HU HU0400070A patent/HUP0400070A2/hu unknown
- 2002-04-30 CA CA002445839A patent/CA2445839A1/en not_active Abandoned
- 2002-04-30 WO PCT/GB2002/001971 patent/WO2002088167A1/en active IP Right Grant
- 2002-04-30 MY MYPI20021593A patent/MY137522A/en unknown
- 2002-04-30 CN CNB028112121A patent/CN1302007C/zh not_active Expired - Fee Related
- 2002-04-30 CZ CZ20032958A patent/CZ20032958A3/cs unknown
- 2002-04-30 IL IL15822202A patent/IL158222A0/xx unknown
- 2002-04-30 DK DK02722463T patent/DK1383786T3/da active
- 2002-04-30 NZ NZ528888A patent/NZ528888A/en unknown
- 2002-04-30 JP JP2002585465A patent/JP4446661B2/ja not_active Expired - Fee Related
- 2002-04-30 DE DE60229372T patent/DE60229372D1/de not_active Expired - Lifetime
- 2002-04-30 PL PL02366937A patent/PL366937A1/xx unknown
- 2002-04-30 SI SI200230765T patent/SI1383786T1/sl unknown
- 2002-04-30 KR KR1020037014199A patent/KR100831534B1/ko not_active IP Right Cessation
- 2002-04-30 MX MXPA03009940A patent/MXPA03009940A/es active IP Right Grant
-
2003
- 2003-10-21 NO NO20034708A patent/NO326015B1/no unknown
-
2004
- 2004-07-13 HK HK04105110.0A patent/HK1062020A1/xx not_active IP Right Cessation
-
2007
- 2007-04-04 AU AU2007201491A patent/AU2007201491A1/en not_active Abandoned
- 2007-09-06 US US11/851,125 patent/US20070297989A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1383786T3 (da) | Antiinflammatoriske 17-beta-carbothioatesterderivater af androstan med en cyklisk estergruppe i 17alfa-stilling | |
NO20015314L (no) | Steroidderivater | |
DK1175220T3 (da) | Nanopartikulære eplerenonkompositioner | |
DE50111949D1 (de) | Komponente einer Strömungsmaschine | |
DE60023625D1 (de) | Keramischer Turbinenleitapparat | |
NO20031869D0 (no) | Antiinflammatoriske midler | |
IS6000A (is) | Ný aralkýlamín af spírófúrópýridínum sem nytsamleg eru í meðferð | |
ATE306928T1 (de) | Fulvestrant formulierung | |
DE60117362D1 (de) | Parenteral anzuwendendes bisphosphonathaltiges arzneimittel | |
DE60116260D1 (de) | Antivirale azaindolderivate | |
DE60045786D1 (de) | Plasmaanzeigetafel | |
ATE365276T1 (de) | Mehrachsige turbine | |
DE60132412D1 (de) | Turbine | |
DK2112154T3 (da) | Estre i position 20 af camptothecin | |
NO20034413D0 (no) | Beta-karbolinderivater og deres farmasöytiske anvendelse mot depresjon og angst | |
NO20022295L (no) | Synkronmotor med supraledende komponenter | |
ITMI20001827A0 (it) | Medicamento antinfiammatorio | |
DK1475379T3 (da) | Anvendelse af scopinesterderivater til fremstilling af lægemidler | |
DK1196431T3 (da) | En i det væsentlige krystallinsk form af melagatran | |
ATE293126T1 (de) | Cyclische hexapeptidderivate | |
EE200300465A (et) | Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid | |
ITMI20001741A0 (it) | Composizioni farmaceutiche comprendenti agenti antiinfiammatori e loro usi | |
DK1227795T3 (da) | Lipidkompleks af alkycycliner | |
DK1341539T3 (da) | Antiinflammatoriske midler | |
DE60140294D1 (de) | Uhrwerk mit Spannungsgenerator |